These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 3743371)
21. [The effect of benzylpenicillin and doxycycline on toxicity and antineoplastic action of cyclophosphamide and methotrexate in mice]. Pakulska W Acta Pol Pharm; 1992; 49(1-2):35-40. PubMed ID: 8769079 [TBL] [Abstract][Full Text] [Related]
22. Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood. Anderson LW; Ludeman SM; Colvin OM; Grochow LB; Strong JM J Chromatogr B Biomed Appl; 1995 May; 667(2):247-57. PubMed ID: 7663697 [TBL] [Abstract][Full Text] [Related]
23. In situ preparation and fate of cis-4-hydroxycyclophosphamide and aldophosphamide: 1H and 31P NMR evidence for equilibration of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and its hydrate in aqueous solution. Borch RF; Hoye TR; Swanson TA J Med Chem; 1984 Apr; 27(4):490-4. PubMed ID: 6708051 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and antitumor activity of cyclophosphamide analogues. 3. Preparation, molecular structure determination and anticancer screening of racemic cis- and trans-4-phenylcyclophosphamide. Boyd VL; Zon G; Himes VL; Stalick JK; Mighell AD; Secor HV J Med Chem; 1980 Apr; 23(4):372-5. PubMed ID: 7381836 [TBL] [Abstract][Full Text] [Related]
25. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide. Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053 [TBL] [Abstract][Full Text] [Related]
26. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)]. Voelcker G; Haeglsperger R Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370 [TBL] [Abstract][Full Text] [Related]
27. Cytotoxic evaluation of some N-acyl and N-acyloxy analogues of 3,5-bis(arylidene)-4-piperidones. Dimmock JR; Arora VK; Chen M; Allen TM; Kao GY Drug Des Discov; 1994 Jul; 12(1):19-28. PubMed ID: 7578805 [TBL] [Abstract][Full Text] [Related]
28. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites. Boyd VL; Robbins JD; Egan W; Ludeman SM J Med Chem; 1986 Jul; 29(7):1206-10. PubMed ID: 3543359 [TBL] [Abstract][Full Text] [Related]
29. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Joqueviel C; Martino R; Gilard V; Malet-Martino M; Canal P; Niemeyer U Drug Metab Dispos; 1998 May; 26(5):418-28. PubMed ID: 9571223 [TBL] [Abstract][Full Text] [Related]
30. Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia. Zaharko DS; Covey JM; Hörpel G Invest New Drugs; 1984; 2(2):149-54. PubMed ID: 6469508 [TBL] [Abstract][Full Text] [Related]
31. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo. Voelcker G; Wagner T; Hohorst HJ Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216 [TBL] [Abstract][Full Text] [Related]
32. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Hemminki K Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012 [TBL] [Abstract][Full Text] [Related]
33. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Hilton J Cancer Res; 1984 Nov; 44(11):5156-60. PubMed ID: 6488175 [TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia. Grossie VB; Rosenblum MG; Loo TL Cancer Treat Rep; 1982 Aug; 66(8):1631-4. PubMed ID: 6809329 [TBL] [Abstract][Full Text] [Related]
35. Studies on cyclophosphamide metabolites and their related compounds. 2. Preparation of an active species of cyclophosphamide and related compounds. Takamizawa A; Matsumoto S; Iwata T; Tochino Y; Katagiri K; Yamaguchi K J Med Chem; 1975 Apr; 18(4):376-83. PubMed ID: 1121004 [TBL] [Abstract][Full Text] [Related]
36. Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds. Draeger J; Peter G; Hohorst HJ Cancer Treat Rep; 1976 Apr; 60(4):355-9. PubMed ID: 1277211 [TBL] [Abstract][Full Text] [Related]
37. Comparison of cytotoxic action of iphosphamide and cyclophosphamide. Phelan ET; Vietti TJ; Valeriote FA; Coulter D Anticancer Res; 1981; 1(3):149-54. PubMed ID: 7342853 [TBL] [Abstract][Full Text] [Related]
38. Synthesis and cytotoxic evaluation of mesna adducts of some 1-aryl-4,4-dimethyl-5-(1-piperidino)-1-penten-3-one hydrochlorides. Dimmock JR; Kumar P; Chen M; Quail JW; Yang J; Allen TM; Kao GY Pharmazie; 1995 Jul; 50(7):449-53. PubMed ID: 7675885 [TBL] [Abstract][Full Text] [Related]
39. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy. Dirven HA; Venekamp JC; van Ommen B; van Bladeren PJ Chem Biol Interact; 1994 Dec; 93(3):185-96. PubMed ID: 7923439 [TBL] [Abstract][Full Text] [Related]
40. Single versus combination chemotherapy of L1210 leukemia. Koza I; Balázová E; Ujházy V Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]